Browsing Tag
OS Therapies
4 posts
OS Therapies eyes global approvals for OST-HER2 after breakthrough osteosarcoma vaccine trial
OS Therapies’ OST-HER2 cancer vaccine shows strong survival gains in Phase IIb osteosarcoma trial—discover what comes next for global approval.
OS Therapies reports statistically significant 75% two-year survival with OST-HER2, eyes 2026 FDA approval
Find out how OS Therapies’ OST-HER2 achieved 75 % two-year survival in osteosarcoma and could secure FDA approval by 2026.
OS Therapies reports strong survival benefit in Phase 2b osteosarcoma trial, eyes FDA accelerated approval
OS Therapies’ OST-HER2 trial shows 66.6% two-year survival in recurrent pulmonary osteosarcoma. Find out what this could mean for FDA approval.
OS Therapies’ OST-HER2 achieves milestone in osteosarcoma treatment
OS Therapies, Inc., a clinical-stage biotechnology company, has announced data from its Phase 2b trial of OST-HER2, an…